Unknown

Dataset Information

0

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.


ABSTRACT: Sclerostin, a protein produced by osteocytes, inhibits bone formation. Administration of sclerostin antibody results in increased bone formation in multiple animal models. Romosozumab, a humanized sclerostin antibody, has a dual effect on bone, transiently increasing serum biochemical markers of bone formation and decreasing serum markers of bone resorption, leading to increased BMD and reduction in fracture risk in humans. We aimed to evaluate the effects of romosozumab on bone tissue. In a subset of 107 postmenopausal women with osteoporosis in the multicenter, international, randomized, double-blind, placebo-controlled Fracture Study in Postmenopausal Women with Osteoporosis (FRAME), transiliac bone biopsies were performed either after 2 (n?=?34) or 12 (n?=?73) months of treatment with 210 mg once monthly of romosozumab or placebo to evaluate histomorphometry and microcomputed tomography-based microarchitectural endpoints. After 2 months, compared with either baseline values assessed after a quadruple fluorochrome labeling or placebo, significant increases (P

SUBMITTER: Chavassieux P 

PROVIDER: S-EPMC7027577 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.

Chavassieux Pascale P   Chapurlat Roland R   Portero-Muzy Nathalie N   Roux Jean-Paul JP   Garcia Pedro P   Brown Jacques P JP   Libanati Cesar C   Boyce Rogely W RW   Wang Andrea A   Grauer Andreas A  

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20190624 9


Sclerostin, a protein produced by osteocytes, inhibits bone formation. Administration of sclerostin antibody results in increased bone formation in multiple animal models. Romosozumab, a humanized sclerostin antibody, has a dual effect on bone, transiently increasing serum biochemical markers of bone formation and decreasing serum markers of bone resorption, leading to increased BMD and reduction in fracture risk in humans. We aimed to evaluate the effects of romosozumab on bone tissue. In a sub  ...[more]

Similar Datasets

| S-EPMC6037073 | biostudies-literature
| S-EPMC8260819 | biostudies-literature
| S-EPMC8567484 | biostudies-literature
| S-EPMC6009094 | biostudies-literature
| S-EPMC4286624 | biostudies-literature
| S-EPMC9292813 | biostudies-literature
| S-EPMC7937846 | biostudies-literature
| S-EPMC6362945 | biostudies-literature
| S-EPMC11344515 | biostudies-literature
| S-EPMC6533425 | biostudies-literature